Lobbying Pays Off As UK Ministers Speak Out On Post-Brexit Regulatory Collaboration
Pressure from industry and other bodies seems to be paying off after two senior government ministers publicly called for a “close working relationship” between the UK and the EU after Brexit. The move has been welcomed by the life sciences industry, which has been lobbying for some sort of regulatory cooperation agreement to avoid regulatory divergence and possible delays to new product launches.
You may also be interested in...
Yet Another UK Call For Views On What Brexit Means For Pharma, Regulation & Health
Another inquiry investigation into the consequences of Brexit in the life sciences area has been launched, this time by the UK House of Commons health committee. Stakeholders are asked to comment on issues like the impact on the regulation of medicines and medical devices, how to ensure continued access to medicines, and whether transitional arrangements will be needed.
Brexit: How Do Pharma Firms Plan For An Unknown Scenario?
As the Brexit negotiations continue, the pharmaceutical industry is anxious to have a cut-off date when it should start taking action to deal with the legal repercussions of the UK becoming a third country within the context of the EU medicines network. There are no clear answers yet, and companies are being asked to continue to wait and watch.
Pharma Execs Urge Post-Brexit Regulatory Deal, As EMA Focuses On Redistribution Of MHRA Work
Spurred by an apparent shift towards a more pro-business stance among government ministers, a number of top pharmaceutical executives and heads of UK industry bodies have publicly called for some form of regulatory alignment deal between the UK and the EU after Brexit.